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INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths world-
wide and can be histologically subdivided into small cell lung cancer
and non-small cell lung cancer (NSCLC). Several driver oncogenes,
including epidermal growth factor receptor (EGFR) mutations and
anaplastic lymphoma kinase (ALK) - fusion genes, have been iden-
tified in NSCLC ; recently, individual therapy based on gene pro-
filing with corresponding targeted drugs has been introduced into
clinical practice (1-3).
Rearranged during transfection (RET) was discovered in 1985
as an oncogene that was produced by recombination during the
transfection of NIH 3T3 cells with human lymphoma DNA (4). RET
fusion genes are detected in 20-40% of papillary thyroid cancers
(5, 6). Recently, they were also identified in some cases of NSCLCs
(7-10). The most common fusion partner of RET is KIF5B, followed
by CCDC6, TRIM33, and NCOA4 (9, 11, 12). RET fusion is detected
in 1-2% of NSCLCs and is mutually exclusive to the mutation or
rearrangementof other commonly alteredgenes, includingEGFR,
KRAS, ALK, and ROS1 (9). KIF5B-RET fusion transgenic mice were
shown to develop lung adenocarcinoma (13), which indicated that
RET fusion genes were one of the oncogenic drivers of lung ade-
nocarcinoma.
Recent clinical trials of vandetanib or cabozantinib for RET -
fusion positive NSCLC demonstrated a clinical response. Patients
treated with vandetanib had a response rate of 53% (9/17 cases)
and a progression-free survival (PFS) of 4.7 months (14) ; those
treated with cabozantinib had a response rate of 28% (7/25 cases)
and a PFS of 5.5 months (15). These results were not comparable
to those in NSCLCs with EGFR mutations or ALK translocations
treated with EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs,
respectively, which indicated the need to develop more beneficial
RET inhibitors for RET fusion-positive NSCLC.
CH5424802 (alectinib) is a second generation ALK-TKI that also
displayed active against ALK with a L1196M gatekeeper mutation
(16). In a phase I clinical trial, although the maximum tolerated
dose was not determined, alectinib showed remarkable efficacy,
with a response rate of 93.5% and PFS greater than 27 months, and
300 mg alectinib twice daily has been approved for the treatment of
ALK -positive NSCLC in Japan (17). Although alectinib is thought
to be a highly selective inhibitor of ALK relative to other compounds
such as crizotinib and ceritinib, which have been approved for ALK -
positive NSCLC, it also has a high activity against RET (18). A global
trial showed the efficacy and safety of alectinib 600 mg twice daily
and the U.S. Food and Drug Administration (FDA) approved this
regime for ALK -positive NSCLC (19, 20). Recently, Lin et al. re-
ported the compassionate or off - label use of alectinib in patients
with NSCLC harboring a RET - fusion gene (21). In this report, alect-
inib demonstrated preliminary antitumor activity and suggested
the importance of conducting prospective studies.
Therefore, we are conducting a phase I/II trial to assess the effi-
cacy of alectinib in RET fusion-positive NSCLC patients (ALL-RET
trial : Alectinib in lung cancer with RET fusion) (UMIN000020628).
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The primary objective in the phase I portion (step 1) is to evaluate
the safety, tolerability, pharmacokinetic parameters, maximum tol-
erated dose (MTD), and efficacy of CH5424802 (alectinib) in pa-
tients with advanced NSCLC harboring a RET fusion gene. In the
phase II portion (step 2), it is to evaluate the efficacy and safety of
CH5424802 at the MTD in patients with advanced NSCLC har-
boring a RET fusion gene.
Study design
This study is an open- label, multi - institutional phase I/II study ;
as of January 2017, the participating institutions included seven spe-
cialized centers in Japan. These institutions are listed in Table 1.
Ethical considerations and registration
This study will be conducted in accordance with the Interna-
tional Committee for Harmonization Good Clinical Practice (ICH-
GCP) guidelines and the Declaration of Helsinki. The study protocol
was approved by the institutional review boards of all participating
institutions. Informed consent will be obtained from all patients
before registration. This study was registered with UMIN Clinical
Trials Registry (UMIN000020628).
Endpoint
The primary endpoints are dose- limiting toxicity (DLT), safety,
and pharmacokinetic parameters in the phase I portion (step 1),
and objective response rate (ORR) in RET-TKI naïve patients ac-
cording to central review in the phase II portion (step 2). Toxicities
will be graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) version 4.0.
DLT is defined as follows : grade4 thrombopenia ; grade3 feb-
rile neutropenia ; grade4 neutropenia lasting 4 days or more ;
grade3 any non-hematologic toxicity except for controllable
electrolyte abnormality, nausea, vomiting, and diarrhea. DLT will
be evaluated during the first cycle (21 days) of therapy.
The secondary endpoints are response rate according to review
by investigators, PFS, disease control rate, overall survival, ORR
in patients previously treated with RET-TKIs, subgroup efficacy
in patients with different RET fusion partners, and safety.
ELIGIBILITY CRITERIA
Inclusion criteria
Prior to enrolment in the study, patients must fulfill all of the fol-
lowing criteria : provision of written informed consent ; aged 20
years or older ; histologically or cytologically diagnosed NSCLC
with unresectable locally advanced or metastatic disease ; tumor
samples that tested positive for a RET fusion gene and negative for
an EGFR mutation and an ALK fusion gene ; failure to respond to a
course (or multiple courses) of chemotherapy or progression of
NSCLC after a course (or multiple courses) of chemotherapy ; life
expectancy of 3 months or longer ; Eastern Cooperative Oncology
Group (ECOG) Performance Status of 0-2 ; not pregnant ; have
adequate bonemarrow, liver, renal, and respiratory functions that
meet the levels stated below :
i) Neutrophil count1,500/mm3
ii) Hemoglobin level9.0 g/dL
iii) Platelet count100,000/mm3
iv) Serum creatinine level1.5 mg/dL
v) ALT, AST, and ALP levels3-fold of the upper limit of the
reference value at each institution
vi) Serum bilirubin level1.5- fold of the upper limit of the ref-
erence value at each institution
vii) SpO292% ;
and, for the phase II portion (step 2) : have one ormoremeasur-
able lesions in accordance with the revised RECIST guidelines
(version 1.1).
Exclusion criteria
Patients will be excluded for any of the following reasons : pre-
vious receipt of CH5424802 ; a history of hypersensitivity to addi-
tives contained in CH5424802 ; infection requiring systemic ad-
ministration of antibiotics or antivirals ; positive laboratory tests
for the hepatitis B antigen or anti -hepatitis C virus antibodies ; pres-
ence of unstable brain metastases or spinal cord compression that
require treatment ; any condition that would preclude receipt of
the study treatment ; a QTc interval greater than 480 ms, a history
of long QT syndrome, a history of clinically significant ventricular
arrhythmia, currently in receipt of antiarrhythmic drugs, or have
an implanted defibrillator ; interstitial lung disease or a history of
that disease ; poorly controlled diabetes or hypertension that can-
not bemanagedwithmedication ; difficulty in receiving oral medi-
cation ; exhibition of adverse reactions to prior treatment of severity
of grade 2 or higher ; if the following times have not elapsed since
prior treatment or the conclusion of such treatment to the date of
enrolment in the study :
i) Surgery or radiation therapy : 4 weeks
ii) Bronchoscopic treatment : 2 weeks
iii) Chemotherapy : 4 weeks
iv) Lenvatinib or vandetanib : 3 weeks
v) Nitrosourea or mitomycin C : 6 weeks
vi) Endocrine therapy or immunotherapy : 2 weeks
vii) Transfusion or hematopoietic growth factor : 2 weeks
viii) Other trial medications : 4 weeks ;
pleural effusion, pericardial effusion, or ascites that requires
Table 1. Participating Institutions and Coordinating Investigators
Coordinating Investigators
Shinji Takeuchi and Seiji Yano, Kanazawa University Hospital
Participating Institution Principal Investigator
1. Kanazawa University Hospital Shinji Takeuchi
2. National Cancer Center Hospital East Koichi Goto
3. The Cancer Institute Hospital of JFCR Makoto Nishio
4. Nagoya University Hospital Yoshinori Hasegawa
5. Hyogo Cancer Center Miyako Satouchi
6. Okayama University Hospital Katsuyuki Kiura
7. National Kyushu Cancer Center Takashi Seto
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treatment ; deep vein thrombus or pulmonary thromboembolism
that requires treatment ; multiple malignancies with differing his-
tologies ; a history of other malignancies in the past 5 years ; or
patients deemed ineligible for participation in this study by an
investigator for any other reason.
Patient registration
The investigators will send a patient registration form to the in-
dependent data center at Innovative Clinical Research Center in
the Kanazawa University Hospital. Patient registration began on
February 2016 and shall continue until January 2018.
Treatment
In the phase I portion (step 1), CH5424802 (cohort 1 : 600 mg ;
cohort 2 : 450 mg) will be administered orally twice daily in a 21-
day cycle. Three to six patients will be enrolled in each cohort. The
recommended dose (RD) or maximum tolerated dose (MTD) of
CH5424802 will be determined using a de-escalation scheme
(Figure 1). In the phase II portion (step 2), the RD/MTD of
CH5424802 in a cycle of 21 days will continue until the criteria for
a respite, dosage reduction, or discontinuation of the protocol treat-
ment are met.
Follow-up
After completion of the scheduled treatment, follow-up of the
patients will occur until January 2019. The clinical outcomes for
each patient will be measured at 24-week intervals after confirma-
tion of disease progression or initiation of post-study treatment.
Sample size determination
In the phase I portion (step 1), the sample size was determined
based on a conventional 3+3 phase I design for oncology drugs.
In the phase II portion (step 2), the planned sample size of 17 RET-
TKI-naïve patients was determined to reject a null ORR of 30% at
a onesided significance level of 0.05 under an expected ORR of 60%
with a power of 0.80. A maximum of 10 patients previously treated
with other RET-TKIs (vandetanib and/or lenvatinib) will also be
enrolled for exploratory analysis in the phase II portion (step 2).
Statistical analysis
In the phase I portion (step 1), the population analyzed for the
primary endpoint will include the enrolled patients with complete
safety data on the DLT. In the phase II portion (step 2), the analysis
population for efficacy is the full analysis set, and we will estimate
the confidence interval (CI) of the ORR using an exact binomial
distribution with a one-sided significance level of 5%. A treatment
will be declared promising if the estimated lower limit of the ORR
exceeds the threshold value of 30%.
RESULTS AND DISCUSSION
This is the first study to investigate the safety and preliminary
efficacy of alectinib in RET fusion gene-positive NSCLC patients.
To identify 20 RET fusion-positive NSCLC cases, we will screen
2000 NSCLC patients participating in the nationwide gene screen-
ing network, LC-SCRUM-Japan ; as of August 2016, the network
contained more than 200 participating institutions.
In ALK fusion-positive NSCLC, alectinib activity has been shown
against crizotinib-resistant ALK mutations, including L1196M and
C1156Y (16). Moreover, alectinib has activity against RET muta-
tions, including V804L and V804M (18), which are resistant to
other RET-TKIs such as vandetanib and cabozantinib, and is ex-
pected to have clinical efficacy in patients who are refractory to
other RET-TKIs. In the ALL-RET study, we will also evaluate the
preliminary efficacy (the response rate) of alectinib in patients with
RET fusion-positive NSCLC who are refractory to other RET-TKIs
(vandetanib and/or lenvatinib).
If the trial is successful, alectinib may yield substantial and
important changes in the management of patients with RET fusion
gene positive NSCLC.
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DLTs, dose-limiting toxicities. MTD, maximum tolerated dose. RD, recommended dose.  
Figure 1. Study design.
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